AU2022248891A1 - Composition for preventing or treating chronic kidney disease, comprising compound that induces expression of anti-aging gene klotho - Google Patents

Composition for preventing or treating chronic kidney disease, comprising compound that induces expression of anti-aging gene klotho Download PDF

Info

Publication number
AU2022248891A1
AU2022248891A1 AU2022248891A AU2022248891A AU2022248891A1 AU 2022248891 A1 AU2022248891 A1 AU 2022248891A1 AU 2022248891 A AU2022248891 A AU 2022248891A AU 2022248891 A AU2022248891 A AU 2022248891A AU 2022248891 A1 AU2022248891 A1 AU 2022248891A1
Authority
AU
Australia
Prior art keywords
chemical formula
straight
branched alkyl
halogen
klotho
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022248891A
Other languages
English (en)
Other versions
AU2022248891A9 (en
Inventor
Dong Ju Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Klotho Sciences Co Ltd
Original Assignee
Klotho Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020220040453A external-priority patent/KR102463786B1/ko
Application filed by Klotho Sciences Co Ltd filed Critical Klotho Sciences Co Ltd
Publication of AU2022248891A1 publication Critical patent/AU2022248891A1/en
Publication of AU2022248891A9 publication Critical patent/AU2022248891A9/en
Priority to AU2025202595A priority Critical patent/AU2025202595A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022248891A 2021-04-01 2022-04-01 Composition for preventing or treating chronic kidney disease, comprising compound that induces expression of anti-aging gene klotho Abandoned AU2022248891A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025202595A AU2025202595A1 (en) 2021-04-01 2025-04-11 Composition for preventing or treating chronic kidney disease, comprising compound that induces expression of anti-aging gene klotho

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2021-0042955 2021-04-01
KR20210042955 2021-04-01
KR10-2022-0040453 2022-03-31
KR1020220040453A KR102463786B1 (ko) 2021-04-01 2022-03-31 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물
PCT/KR2022/004706 WO2022211574A1 (ko) 2021-04-01 2022-04-01 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025202595A Division AU2025202595A1 (en) 2021-04-01 2025-04-11 Composition for preventing or treating chronic kidney disease, comprising compound that induces expression of anti-aging gene klotho

Publications (2)

Publication Number Publication Date
AU2022248891A1 true AU2022248891A1 (en) 2023-10-26
AU2022248891A9 AU2022248891A9 (en) 2023-11-09

Family

ID=83456608

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022248891A Abandoned AU2022248891A1 (en) 2021-04-01 2022-04-01 Composition for preventing or treating chronic kidney disease, comprising compound that induces expression of anti-aging gene klotho
AU2025202595A Pending AU2025202595A1 (en) 2021-04-01 2025-04-11 Composition for preventing or treating chronic kidney disease, comprising compound that induces expression of anti-aging gene klotho

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025202595A Pending AU2025202595A1 (en) 2021-04-01 2025-04-11 Composition for preventing or treating chronic kidney disease, comprising compound that induces expression of anti-aging gene klotho

Country Status (8)

Country Link
US (1) US12691102B2 (cg-RX-API-DMAC7.html)
EP (1) EP4317140A4 (cg-RX-API-DMAC7.html)
JP (1) JP7728030B2 (cg-RX-API-DMAC7.html)
CN (1) CN117157280B (cg-RX-API-DMAC7.html)
AU (2) AU2022248891A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020026A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213910A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022211574A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088770A (en) * 1971-05-04 1978-05-09 Eli Lilly And Company Substituted 2-anilinobenzoxazoles used as immunosuppressive agents
PL357678A1 (en) * 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators
US8318703B2 (en) * 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US20070066577A1 (en) * 2003-04-03 2007-03-22 Hea Young Park Choo Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
CA2783555A1 (en) * 2009-12-16 2011-07-14 Eli Lilly And Company Therapeutic uses of soluble alpha-klotho
KR101372721B1 (ko) * 2010-06-18 2014-03-14 이화여자대학교 산학협력단 Interleukin―6 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
KR101446301B1 (ko) * 2013-04-11 2014-10-06 서울대학교산학협력단 Cxcr3/cxcl10 길항제 화합물, 이의 제조방법 및 이를 포함하는 골 전이의 예방 및 치료용 약학 조성물
WO2016176473A1 (en) * 2015-04-28 2016-11-03 Sanford-Burnham Medical Researc Institute Apelin receptor agonists and methods of use thereof
KR101770310B1 (ko) * 2015-08-24 2017-08-24 이화여자대학교 산학협력단 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
WO2018087132A1 (en) * 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP3611521B1 (en) 2018-08-16 2026-05-27 GE Vernova Technology GmbH Apparatus for monitoring a condition of an electrical power transmission medium
IT201900007446A1 (it) * 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
KR20200145909A (ko) 2019-06-20 2020-12-31 주식회사 레이지소사이어티 면도날 자동주문 장치
WO2021066608A1 (ko) * 2019-10-02 2021-04-08 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물 및 이의 용도
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
WO2022211574A1 (ko) 2022-10-06
AU2025202595A1 (en) 2025-05-01
CA3213910A1 (en) 2022-10-06
AU2022248891A9 (en) 2023-11-09
EP4317140A4 (en) 2025-04-09
CN117157280B (zh) 2026-07-21
JP2024512813A (ja) 2024-03-19
US12691102B2 (en) 2026-07-28
US20240216341A1 (en) 2024-07-04
JP7728030B2 (ja) 2025-08-22
CN117157280A (zh) 2023-12-01
BR112023020026A2 (pt) 2024-01-23
EP4317140A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
KR102530597B1 (ko) 항노화 유전자 klotho의 발현을 유도하는 화합물 및 이의 용도
AU2022251900A1 (en) Composition for preventing or treating neurodegenerative disease comprising compound inducing expression of anti-aging gene klotho
TW202400605A (zh) 噻吩并嘧啶二酮acc抑制劑之固體型式及其製造方法
AU2017272151A1 (en) Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
CN102361853A (zh) 甲苯胺磺酰胺及其用途
JP2016516812A (ja) アミドピリジンオール誘導体またはその薬剤学的に許容可能な塩、及びそれを有効成分として含有する薬学組成物
JP2012514019A (ja) トルイジンスルホンアミド、及び阻害剤としてのそれらの使用
AU2025202595A1 (en) Composition for preventing or treating chronic kidney disease, comprising compound that induces expression of anti-aging gene klotho
JPWO2007043568A1 (ja) S1p3受容体拮抗剤
KR102463786B1 (ko) 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물
US20240025845A1 (en) Metastasis-inhibiting composition of novel methylsulfonamide derivative compound
WO1998057922A1 (fr) Derives de triphenylmethane et leur utilisation
JP7803597B2 (ja) 抗老化遺伝子klothoの発現を誘導する新規化合物
JP2009007290A (ja) フェニルプロペンアミド誘導体を有効成分とする糖化最終産物形成阻害剤

Legal Events

Date Code Title Description
SREP Specification republished
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted